CRISPR Editing of Msh3 Gene Reduces Huntington's Disease Progression in Mice
Researchers used somatic CRISPR-Cas9 editing to knock out the Msh3 gene in Huntington's disease mice at three different disease stages, finding that the intervention slowed CAG repeat expansion in the brain and reduced key markers of pathology at all ages tested. MSH3 is a mismatch repair protein that drives the progressive expansion of the disease-causing CAG repeat in neurons, and human genetic data already support it as a therapeutic target. The findings provide preclinical evidence that an MSH3-targeting therapy could be disease-modifying in humans, with earlier intervention yielding greater benefit.
Huntington's disease (HD) is a fatal inherited neurodegenerative disorder caused by an expanded CAG repeat in the Huntingtin gene, and ongoing somatic expansion of that repeat in neurons is known to accelerate clinical onset. In a new preprint posted to bioRxiv, scientists knocked out the Msh3 gene — which encodes the mismatch repair protein MSH3 that drives somatic CAG expansion — using CRISPR-Cas9 delivered to HttQ111 mice at 6, 16, and 24 weeks of age, representing progressively more advanced stages of somatic expansion. Intervention at all three time points reduced striatal CAG expansion, lowered nuclear huntingtin accumulation, and suppressed transcriptional dysregulation, though earlier treatment produced the largest effects. Notably, Msh3 knockout also reduced production of the exon 1 Htt1a transcript, a toxic species implicated in HD pathology, suggesting an additional mechanism of benefit. Because the approach would realistically affect only a subset of brain cells in humans, the study also offers insight into how partial MSH3 inhibition might still meaningfully alter disease trajectory. The authors note the results are directly relevant to ongoing efforts to develop MSH3-targeting therapeutics for HD patients.
What's missing
As a preprint, this work has not yet undergone peer review. Key limitations include that HttQ111 mice do not fully recapitulate human HD symptomatology or the degree of neuronal loss seen clinically. The study does not report behavioral or motor outcome measures, making it unclear whether the molecular improvements translate to functional benefit. Long-term safety of Msh3 knockout — given MSH3's role in genome-wide mismatch repair — is not assessed.
What different sources said
- bioRxivCenter
Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.